文献速递淋巴瘤

套细胞淋巴瘤中來那度胺疗效的候选种系生物标志物:意大利淋巴瘤基金会MCL0208试验

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.
PubMed 文献 · Blood Adv · 2023-01-01

在意大利淋巴瘤基金会MCL0208 3期试验中,对自体干细胞移植(ASCT)后套细胞淋巴瘤(MCL)患者分析种系单核苷酸多态性(SNP)与来那度胺(LEN)维持疗效的关系。278例患者中ABCB1和VEGF多态性分别占69%和79%,在LEN组预测有利的无进展生存(PFS):3年PFS 85% vs 70%(P<.05)和85% vs 60%(P<.01)。同时携带ABCB1和VEGF野生型者3年PFS最差(46%),且LEN未改善PFS vs 观察组(44% vs 60%,P=.62)。

要点

  • ABCB1和VEGF多态性在LEN组预测更优3年PFS,分别为85% vs 70%和85% vs 60%。
  • 同时携带ABCB1和VEGF野生型者3年PFS仅46%,LEN未优于观察(44% vs 60%,P=.62)。
  • CRBN多态性(n=28)与来那度胺减量或停药相关,并预测较低≥3级感染风险。

核心结论

  • 特定SNP可作为MCL患者ASCT后免疫化疗毒性和LEN疗效的候选预测生物标志物。

研究设计与样本

  • 意大利淋巴瘤基金会MCL0208 3期试验的宿主药物遗传学分析,纳入278例患者。
  • 通过实时聚合酶链反应检测外周血种系DNA基因型,分析跨膜转运体、代谢酶或细胞表面受体基因的SNP。

主要发现

  • 278例患者中ABCB1和VEGF多态性分别占69%和79%,在LEN组预测有利PFS:3年PFS 85% vs 70%(P<.05)和85% vs 60%(P<.01)。
  • 同时携带ABCB1和VEGF野生型者3年PFS最差(46%),总生存76%;LEN未改善PFS vs 观察组(3年PFS 44% vs 60%,P=.62)。
  • CRBN多态性(n=28)与来那度胺减量或停药相关。
  • ABCB1、NCF4和GSTP1多态性预测诱导期较低血液学毒性。
  • ABCB1和CRBN多态性预测较低≥3级感染风险。

关键数值与推荐

  • ABCB1多态性:LEN组3年PFS 85% vs 野生型70%(P<.05)。
  • VEGF多态性:LEN组3年PFS 85% vs 野生型60%(P<.01)。
  • ABCB1和VEGF双野生型:3年PFS 46%,总生存76%;LEN组3年PFS 44% vs 观察组60%(P=.62)。
  • CRBN多态性(n=28)与来那度胺减量或停药相关;ABCB1和CRBN多态性预测较低≥3级感染风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS). The host pharmacogenetic background was analyzed to decipher whether single-nucleotide polymorphisms (SNPs) of genes encoding transmembrane transporters, metabolic enzymes, or cell-surface receptors might predict drug efficacy. Genotypes were obtained via real-time polymerase chain reaction of the peripheral blood germ line DNA. Polymorphisms of ABCB1 and VEGF were found in 69% and 79% of 278 patients, respectively, and predicted favorable PFS vs homozygous wild-type (WT) in the LEN arm was 3-year PFS of 85% vs 70% (P < .05) and 85% vs 60% (P < .01), respectively. Patients carrying both ABCB1 and VEGF WT had the poorest 3-year PFS (46%) and overall survival (76%); in fact, in these patients, LEN did not improve PFS vs OBS (3-year PFS, 44% vs 60%; P = .62). Moreover, the CRBN polymorphism (n = 28) was associated with lenalidomide dose reduction or discontinuation. Finally, ABCB1, NCF4, and GSTP1 polymorphisms predicted lower hematological toxicity during induction, whereas ABCB1 and CRBN polymorphisms predicted lower risk of grade ≥3 infections. This study demonstrates that specific SNPs represent candidate predictive biomarkers of immunochemotherapy toxicity and LEN efficacy after ASCT in MCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ferrero S, Grimaldi D, Arrigoni E, et al. Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. Blood Adv. 2023. PMID: 37058477. doi:10.1182/bloodadvances.2022009504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。